Trial Profile

Phase 1, Open-label Study Evaluating the Safety and Feasibility of CART-EGFR-IL13Ra2 Cells in Patients With EGFR-Amplified Recurrent Glioblastoma

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 27 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Anti-EGFR/IL-13R alpha-2-CAR-T-cell-therapy-Tmunity-Therapeutics/University-of-Pennsylvania (Primary)
Indications Glioblastoma
Focus Adverse reactions; Therapeutic Use

Most Recent Events

20 May 2025 Time fraame for all the primary endpoints has been changed.
08 Apr 2025 Given protocol has been amended as above-1) Number of treatment arms has been changed from 4 to 5. 2)Planned number of patients has been changed from 18 to 21. 3) Collaborator has been changed (Kite Pharma (a Gilead Company) ) 4) Primary endpoints has been amended.
08 Apr 2025 Planned number of patients changed from 18 to 21.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com